Vertex Pharmaceuticals Incorporated (ETR: VX1)
Germany
· Delayed Price · Currency is EUR
377.20
+3.55 (0.95%)
Dec 20, 2024, 5:35 PM CET
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 5,400 employees as of December 31, 2023. The number of employees increased by 600 or 12.50% compared to the previous year.
Employees
5,400
Change (1Y)
600
Growth (1Y)
12.50%
Revenue / Employee
€1,764,276
Profits / Employee
€79,665
Market Cap
98.22B
Employees Chart
Employees History
Vertex Pharmaceuticals News
- 1 day ago - Vertex wins approval of new cystic fibrosis therapy Alyftrek - Seeking Alpha
- 1 day ago - Vertex Pharmaceuticals (VRTX) Gains FDA Approval for ALYFTREK⢠- GuruFocus
- 1 day ago - Vertex Pharmaceuticals Inc (VRTX) Announces FDA Approval of ALYFTREK for Cystic Fibrosis Treatment - GuruFocus
- 1 day ago - US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment - Reuters
- 1 day ago - Vertex Pharmaceuticals Inc (VRTX) Expands TRIKAFTA® Approval for Cystic Fibrosis Treatment - GuruFocus
- 1 day ago - Vertex Pharmaceuticals (VRTX) Stock Surges Amid Mixed Analyst Ratings - GuruFocus
- 1 day ago - Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
- 1 day ago - Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants - Business Wire